DAY TWO 2nd November
NEWSLETTER A Continuous Flow Process revolution… through innovation
S
K pharmteco provides expertise in continuous processing and is a recognised worldleader in the development and manufacturing of custom cGMP Intermediates and APIs using continuous processes. In contrast to the traditional batch mode of production, manufacturing by Continuous Flow Process is fluid, offering a greener more environmentallyfriendly alternative. Continuous Processing can lead to safer and more economical and scalable
Live from CPHI Winners of Pharma Awards 2022 declared
production, reducing costs, waste and cycle time to improve quality and yield. However, manufacturing at small scale via continuous flow processing is usually hindered by the excessive lead time required to build dedicated and expensive small-scale units. AMPAC Fine Chemicals (AFC), an SK pharmteco company, has revolutionised continuous process manufacturing development through the use of a unique inhouse modular approach. These modules can produce multi-kilograms of material per day, which can be used for the initial scale-up production of clinical phase programs, as well as commercial drug products under cGMP.
CPHI Frankfurt announces the winners of the prestigious 2022 CPHI Pharma Awards, recognising outstanding achievements from the global pharma industry, across 10 specialist categories. Manni Kantipudi, CEO of Aragen was chosen by the judges as the clear winner of CEO of the Year, one of the most coveted prizes, for delivering outstanding performance with sustained growth and robust strategies. The company has undergone a number of impressive facility improvements, investment rounds and double-digit growth. Moderna’s development of its SPIKEVAX mRNA-based vaccine received the special award for Innovation in Response to COVID-19 category. The messenger RNA (mRNA) technology used in Moderna’s COVID-19 vaccine is based on more than a decade of research
and, having received emergency authorization in 70 countries, more than 807 million doses of the vaccine were shipped globally in 2021. In the API Development category, the Tokuyama Corporation was chosen for its novel synthesis of sodium dependent glucose co-transporters (SGLT2), used in the treatment of diabetes. Previous synthetic methods suffer from need for cryogenic conditions (-78oC), which significantly restricted the supply of this important class of drugs. The Tokuyama Corporation addressed this challenge by developing a new synthetic method which can be undertaken under very mild conditions (40oC). To read more go to: https://www. lskh.digital/news/live-from-cphiwinners-of-pharma-awards-2022declared/
To read more go to: https://www. lskh.digital/article/a-continuousflow-process-revolutionthroughinnovation/
CKH.DIGITAL
c
LSKH.DIGITAL